Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | ULTIMATE study: paclitaxel + bevacizumab in non-squamous NSCLC

Benjamin Besse • 7 May 2020
Lung Cancer Non-Small Cell Lung Cancer Bevacizumab Docetaxel Paclitaxel

Benjamin Besse, MD, PhD, of Institut Gustave Roussy, Villejuif, France, discusses data coming from the ULTIMATE study. The study evaluated weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small cell lung cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Benjamin Besse

2:38
AZD7789 in NSCLC: safety, efficacy, and ongoing evaluation
Benjamin Besse • 24 Oct 2023
1:47
Combining ADCs with other treatment modalities in NSCLC
Benjamin Besse • 24 Oct 2023
2:50
ADC’s for the treatment of NSCLC
Benjamin Besse • 24 Oct 2023
2:28
Optimal duration of immunotherapy administration for patients with NSCLC
Benjamin Besse • 21 Oct 2023

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:45
Assessing treatment options for lung cancer with interstitial lung disease
Matthew Hatton • 18 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals